

Pedro Aide

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3534829/publications.pdf>

Version: 2024-02-01

44
papers

4,691
citations

236925

25
h-index

243625

44
g-index

50
all docs

50
docs citations

50
times ranked

3982
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective surveillance study to detect antimalarial drug resistance, gene deletions of diagnostic relevance and genetic diversity of <i>Plasmodium falciparum</i> in Mozambique: protocol. <i>BMJ Open</i> , 2022, 12, e063456.	1.9	7
2	To spray or target mosquitoes another way: focused entomological intelligence guides the implementation of indoor residual spraying in southern Mozambique. <i>Malaria Journal</i> , 2022, 21, .	2.3	4
3	Community acceptability to antimalarial mass drug administrations in Magude district, Southern Mozambique: A mixed methods study. <i>PLoS ONE</i> , 2021, 16, e0249080.	2.5	2
4	Effect of wall type, delayed mortality and mosquito age on the residual efficacy of a clothianidin-based indoor residual spray formulation (SumiShield, 50WG) in southern Mozambique. <i>PLoS ONE</i> , 2021, 16, e0248604.	2.5	11
5	Assessment of the Feasibility, Acceptability, and Impact of Implementing Seasonal Malaria Chemoprevention in Nampula Province, Mozambique: Protocol for a Hybrid Effectiveness-Implementation Study. <i>JMIR Research Protocols</i> , 2021, 10, e27855.	1.0	9
6	In vivo efficacy and safety of artemether-lumefantrine and amodiaquine-artesunate for uncomplicated <i>Plasmodium falciparum</i> malaria in Mozambique, 2018. <i>Malaria Journal</i> , 2021, 20, 390.	2.3	8
7	Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. <i>Vaccine</i> , 2020, 38, 897-906.	3.8	12
8	A multiphase program for malaria elimination in southern Mozambique (the Magude project): A before-after study. <i>PLoS Medicine</i> , 2020, 17, e1003227.	8.4	38
9	Demographic and health community-based surveys to inform a malaria elimination project in Magude district, southern Mozambique. <i>BMJ Open</i> , 2020, 10, e033985.	1.9	17
10	Field performance of ultrasensitive and conventional malaria rapid diagnostic tests in southern Mozambique. <i>Malaria Journal</i> , 2020, 19, 451.	2.3	17
11	Post-malarial anemia in Mozambican children treated with quinine or artesunate: A retrospective observational study. <i>International Journal of Infectious Diseases</i> , 2020, 96, 655-662.	3.3	3
12	Antibody responses to the RTS,S/AS01E vaccine and <i>Plasmodium falciparum</i> antigens after a booster dose within the phase 3 trial in Mozambique. <i>Npj Vaccines</i> , 2020, 5, 46.	6.0	15
13	Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control. <i>PLoS ONE</i> , 2020, 15, e0235631.	2.5	8
14	Examining community perceptions of malaria to inform elimination efforts in Southern Mozambique: a qualitative study. <i>Malaria Journal</i> , 2019, 18, 232.	2.3	13
15	Setting the scene and generating evidence for malaria elimination in Southern Mozambique. <i>Malaria Journal</i> , 2019, 18, 190.	2.3	35
16	Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2386-2398.	3.3	48
17	Changing plasma cytokine, chemokine and growth factor profiles upon differing malaria transmission intensities. <i>Malaria Journal</i> , 2019, 18, 406.	2.3	6
18	Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. <i>BMC Medicine</i> , 2018, 16, 197.	5.5	65

#	ARTICLE	IF	CITATIONS
19	In-Vivo Efficacy of Chloroquine to Clear Asymptomatic Infections in Mozambican Adults: A Randomized, Placebo-controlled Trial with Implications for Elimination Strategies. <i>Scientific Reports</i> , 2017, 7, 1356.	3.3	21
20	Heterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions. <i>Malaria Journal</i> , 2017, 16, 36.	2.3	10
21	A prospective cohort study to assess the micro-epidemiology of <i>Plasmodium falciparum</i> clinical malaria in Ilha Josina Machel (Manhiãsa, Mozambique). <i>Malaria Journal</i> , 2016, 15, 444.	2.3	13
22	Under treatment of pneumonia among children under 5 years of age in a malaria-endemic area: population-based surveillance study conducted in Manhica district- rural, Mozambique. <i>International Journal of Infectious Diseases</i> , 2015, 36, 39-45.	3.3	19
23	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015, 373, 2025-2037.	27.0	332
24	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1450-1458.	9.1	262
25	Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique. <i>Vaccine</i> , 2014, 32, 2209-2216.	3.8	32
26	Profile: Manhica Health Research Centre (Manhica HDSS). <i>International Journal of Epidemiology</i> , 2013, 42, 1309-1318.	1.9	116
27	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. <i>New England Journal of Medicine</i> , 2012, 367, 2284-2295.	27.0	653
28	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. <i>New England Journal of Medicine</i> , 2011, 365, 1863-1875.	27.0	773
29	Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial. <i>Vaccine</i> , 2011, 29, 6059-6067.	3.8	44
30	Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial. <i>PLoS ONE</i> , 2010, 5, e13838.	2.5	38
31	Long-Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children. <i>Journal of Infectious Diseases</i> , 2009, 200, 329-336.	4.0	117
32	<i>Plasmodium falciparum</i> -Specific Cellular Immune Responses after Immunization with the RTS,S/AS02D Candidate Malaria Vaccine in Infants Living in an Area of High Endemicity in Mozambique. <i>Infection and Immunity</i> , 2009, 77, 4502-4509.	2.2	40
33	A 10 year study of the cause of death in children under 15 years in Manhiãsa, Mozambique. <i>BMC Public Health</i> , 2009, 9, 67.	2.9	71
34	Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. <i>Tropical Medicine and International Health</i> , 2009, 14, 1011-1019.	2.3	94
35	Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children. <i>PLoS ONE</i> , 2009, 4, e5165.	2.5	77
36	Malaria in rural Mozambique. Part I: Children attending the outpatient clinic. <i>Malaria Journal</i> , 2008, 7, 36.	2.3	63

#	ARTICLE	IF	CITATIONS
37	Malaria in rural Mozambique. Part II: children admitted to hospital. <i>Malaria Journal</i> , 2008, 7, 37.	2.3	64
38	Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. <i>Vaccine</i> , 2008, 26, 174-184.	3.8	24
39	Impact of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine on Antibody Responses to Erythrocytic-Stage <i>Plasmodium falciparum</i> Antigens in Infants in Mozambique. <i>Vaccine Journal</i> , 2008, 15, 1282-1291.	3.1	32
40	Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. <i>Lancet, The</i> , 2007, 370, 1543-1551.	13.7	244
41	Relationship between haemoglobin and haematocrit in the definition of anaemia. <i>Tropical Medicine and International Health</i> , 2006, 11, 1295-1302.	2.3	77
42	Intermittent Preventive Treatment for Malaria Control Administered at the Time of Routine Vaccinations in Mozambican Infants: A Randomized, Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2006, 194, 276-285.	4.0	101
43	Duration of protection with RTS,S/AS02A malaria vaccine in prevention of <i>Plasmodium falciparum</i> disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 2012-2018.	13.7	367
44	Efficacy of the RTS,S/AS02A vaccine against <i>Plasmodium falciparum</i> infection and disease in young African children: randomised controlled trial. <i>Lancet, The</i> , 2004, 364, 1411-1420.	13.7	687